Never miss an issue of Master Investor Magazine – sign-up now for free!
AIM-listed cancer immunodiagnostics firm Oncimmune Holdings (LON:ONC) has announced a US distribution agreement for two of its blood test products. The deal with the America’s Choice Provider will put these products within a network covering more than 28 million Americans.
Oncimmune commented that: “Our collaboration with America’s Choice Provider Network is one of several payor and provider agreements we have recently finalized to ensure as many people as possible in the U.S. are able to use our EarlyCDT® tests to facilitate earlier diagnoses,” said Marco Casarin, General Manager, Oncimmune (USA) LLC. “Especially in lung cancer-with nearly 1.6 million Americans having an incidentally detected nodule on the lung-a positive EarlyCDT-Lung outcome enables quicker clinician intervention and better patient outcomes.”
The company’s share price rose by 17.02% to 137.50p (as of 14:50 GMT).